Article
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
The New England journal of medicine - 21 Jun 2018
DiNardo Courtney D, Stein Eytan M, de Botton Stéphane, Roboz Gail J, Altman Jessica K, Mims Alice S, Swords Ronan, Collins Robert H, Mannis Gabriel N, Pollyea Daniel A, Donnellan Will, Fathi Amir T, Pigneux Arnaud, Erba Harry P, Prince Gabrielle T, Stein Anthony S, Uy Geoffrey L, Foran James M, Traer Elie, Stuart Robert K, Arellano Martha L, Slack James L, Sekeres Mikkael A, Willekens Christophe, Choe Sung, Wang Hongfang, Zhang Vickie, Yen Katharine E, Kapsalis Stephanie M, Yang Hua, Dai David, Fan Bin, Goldwasser Meredith, Liu Hua, Agresta Sam, Wu Bin, Attar Eyal C, Tallman Martin S, Stone Richard M, Kantarjian Hagop M
Abstract excerpt
BACKGROUND: Mutations in the gene encoding isocitrate dehydrogenase 1 ( IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1. METHODS: We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML. Safety and efficacy were assessed in all treated patients. The primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.